CCI approves merger of nine pharma entities with Sequent Scientific

Sequent Scientific Limited is a publicly listed company, having operations globally in the animal healthcare industry. The company offers a comprehensive range of Active Pharmaceutical Ingredients (APIs), finished dosage formulations (FDFs), and analytical services to meet the needs of the animal health sector. Sequent Research Limited (SRL) is a wholly owned subsidiary of SSL, which operates as a Contract Research Organization providing analytical services and a wide array of testing to the global pharmaceutical industry.

Viyash Life Sciences Private Limited is a pharmaceutical company and through its subsidiaries is primarily engaged in the development, manufacture and sale of APIs and intermediates for human healthcare in India. Further, it also manufactures FDFs for human healthcare. Symed Labs Limited (Symed), Appcure Labs Private Limited (Appcure), Vindhya Pharma (India) Private Limited (Vindhya Pharma) and Vandana Life Sciences Private Limited (Vandana) are wholly owned subsidiaries of Viyash and S.V. Labs Private Limited (SV Labs) is a wholly owned step-down subsidiary of Viyash (through Vindhya Pharma)

Geninn Life Sciences Private Limited is a holding company and does not have any operations of its own. It has a wholly owned subsidiary, Vindhya Organics Private Limited (Vindhya Organics) which is primarily engaged in the business of development, manufacture and marketing APIs for human healthcare.

Read also: Fortis Healthcare gets CCI nod to acquire additional 31.52 per cent stake in Agilus for Rs 1,780 crore

The Proposed Combination involves a series of inter-connected steps carried out for the amalgamation of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn and SV Labs with SSL as the ultimate surviving entity (Proposed Combination).